The DTWD1 Knockout SK-HEP-1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout population derived from the SK-HEP-1 human liver adenocarcinoma cell line. This heterogeneous pool of DTWD1-disrupted cells avoids clonal selection biases, providing a robust model for loss-of-function studies. The cells are provided as a cryopreserved stock, ready for expansion under standard culture conditions.
SK-HEP-1 is a liver adenocarcinoma cell line originally established from ascites fluid of a patient with hepatic cancer. Displaying epithelial morphology, these cells are widely used in hepatocellular carcinoma research due to their proliferative capacity, invasive characteristics, and relevance to liver tumor biology. They serve as a versatile platform for studying oncogenic processes, drug metabolism, and metastatic behavior.
The DTWD1 gene encodes a DTW domain-containing protein predicted to function in tRNA modification, a process essential for accurate and efficient translation. Although its direct interactors remain unidentified, DTWD1 is hypothesized to associate with tRNA-modifying complexes, potentially involving TRMT family enzymes, translation factors, and ribosomal proteins. By influencing tRNA function, DTWD1 may regulate the translation of specific transcripts, thereby modulating protein synthesis and downstream cellular processes such as growth and stress responses.
In the SK-HEP-1 liver adenocarcinoma model, disruption of DTWD1 provides a valuable system to investigate the role of translational regulation in cancer biology. Alterations in tRNA modification can reprogram the translatome, affecting the expression of oncogenic drivers or tumor suppressors. Consequently, these knockout cells enable studies linking DTWD1-dependent translational control to hallmarks of liver cancer, including uncontrolled proliferation, metabolic rewiring, and resistance to apoptosis.
Researchers can employ this polyclonal knockout population in diverse functional studies, such as CRISPR synthetic lethality screens, drug sensitivity profiling, and ribosome profiling to measure translation efficiency. Standard characterization can be performed via western blotting, RT-qPCR, and RNA-seq, while phenotypic assays include cell viability, migration, invasion, and metabolic activity measurements. This model also supports drug combination testing to identify synthetic vulnerabilities. For additional information or custom inquiries, please contact Ascent Research.
